Back to search
FDAFDA · Food and drugs·Recall number D-0677-2026

Nystatin Cream USP, (100,000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis, Yeruham, Israel, NDC 45802-059-35

Published July 22, 2026 · Recall initiated: June 23, 2026

Summary

FDA records drug Class II recall D-0677-2026, published July 22, 2026 and initiated June 23, 2026. Recalling firm: Padagis US LLC; Status: Ongoing; Reported quantity: 180,936 tubes; Lot: Lot #: 205060, Exp 09/30/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

What to do

Voluntary: Firm initiated · Letter

Get an email if NYSTATIN has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
NYSTATIN
Manufacturer
Padagis US LLC
Distributor
USA Nationwide
Lot
Lot #: 205060, Exp 09/30/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nystatin Cream USP, (100,000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis, Yeruham, Israel, NDC 45802-059-35 recalled?

Yes. FDA published recall D-0677-2026 on July 22, 2026. Reported hazard: Subpotent Drug: Low out of specification assay results performed during long-term stability testing.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: NYSTATIN.